Journal of Cystic Fibrosis
Volume 8, Issue 5 , Pages 338-347 , September 2009

Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation

  • Martin Roderfeld

      Affiliations

    • Justus-Liebig-University Giessen, Department of Internal Medicine, Division of Gastroenterology, 35385 Giessen, Germany
    • Both authors contributed equally to this study.
    • ,
  • Timo Rath

      Affiliations

    • Justus-Liebig-University Giessen, Department of Internal Medicine, Division of Gastroenterology, 35385 Giessen, Germany
    • Both authors contributed equally to this study.
    • ,
  • Richard Schulz

      Affiliations

    • Justus-Liebig-University Giessen, Department of Internal Medicine, Division of Pulmonary & Critical Care Medicine, 35385 Giessen, Germany
    • ,
  • Werner Seeger

      Affiliations

    • Justus-Liebig-University Giessen, Department of Internal Medicine, Division of Pulmonary & Critical Care Medicine, 35385 Giessen, Germany
    • ,
  • Annette Tschuschner

      Affiliations

    • Justus-Liebig-University Giessen, Department of Internal Medicine, Division of Gastroenterology, 35385 Giessen, Germany
    • ,
  • Jürgen Graf

      Affiliations

    • Philipps-University Marburg, Department of Anaesthesiology and Intensive Care, 35033 Marburg, Germany
    • ,
  • Elke Roeb

      Affiliations

    • Justus-Liebig-University Giessen, Department of Internal Medicine, Division of Gastroenterology, 35385 Giessen, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 641 9942338; fax: +49 641 9942339.

Received 27 March 2009 ,Revised 12 June 2009 ,Accepted 16 June 2009.

References 

  1. Genetic testing for cystic fibrosis. NIH Consens Statement. 1997;15:1–37
  2. Accurso FJ. Update in cystic fibrosis 2007. Am J Respir Crit Care Med. 2008;177:1058–1061
  3. Boyle MP. Adult cystic fibrosis. JAMA. 2007;298:1787–1793
  4. Ferkol T, Rosenfeld M, Milla CE. Cystic fibrosis pulmonary exacerbations. J Pediatr. 2006;148:259–264
  5. Clinical practice guidelines for cystic fibrosis. Bethesda, MD: Cystic Fibrosis Foundation; 1997;
  6. Ramsey BW, Boat TF. Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference. J Pediatr. 1994;124:177–192
  7. Sagel SD, Kapsner RK, Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol. 2005;39:224–232
  8. Elkington PT, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. Thorax. 2006;61:259–266
  9. Gueders MM, Foidart JM, Noel A, Cataldo DD. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur J Pharmacol. 2006;533:133–144
  10. Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir Res. 2001;2:10–19
  11. Gaggar A, Li Y, Weathington N, Winkler M, Kong M, Jackson P, et al. Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol. 2007;293:L96–L104
  12. Hilliard TN, Regamey N, Shute JK, Nicholson AG, Alton EW, Bush A, et al. Airway remodelling in children with cystic fibrosis. Thorax. 2007;62:1074–1080
  13. Ratjen F, Hartog CM, Paul K, Wermelt J, Braun J. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax. 2002;57:930–934
  14. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176:957–969
  15. Kerem E, Conway S, Elborn S, Heijerman H. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2005;4:7–26
  16. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–338
  17. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr. 2001;139:359–365
  18. Meisner M, Tschaikowsky K, Palmaers T, Schmidt J. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care. 1999;3:45–50
  19. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168:918–951
  20. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001;32:356–366
  21. Aaron SD, Ramotar K, Ferris W, Vandemheen K, Saginur R, Tullis E, et al. Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2004;169:811–815
  22. Dakin C, Henry RL, Field P, Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol. 2001;31:436–442
  23. Rabin HR, Butler SM, Wohl ME, Geller DE, Colin AA, Schidlow DV, et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol. 2004;37:400–406
  24. Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Resp Med. 2009;103:1231–1238
  25. Brajer B, Batura-Gabryel H, Nowicka A, Kuznar-Kaminska B, Szczepanik A. Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression. J Physiol Pharmacol. 2008;59(Suppl 6):145–152
  26. Perez A, van Heeckeren AM, Nichols D, Gupta S, Eastman JF, Davis PB. Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium. Am J Physiol Lung Cell Mol Physiol. 2008;295:303–313
  27. Gaggar A, Jackson PL, Noerager BD, O'Reilly PJ, McQuaid DB, Rowe SM, et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol. 2008;180:5662–5669
  28. Cataldo DD, Gueders MM, Rocks N, Sounni NE, Evrard B, Bartsch P, et al. Pathogenic role of matrix metalloproteases and their inhibitors in asthma and chronic obstructive pulmonary disease and therapeutic relevance of matrix metalloproteases inhibitors. Cell Mol Biol (Noisy-le-grand). 2003;49:875–884
  29. Elshaw SR, Henderson N, Knox AJ, Watson SA, Buttle DJ, Johnson SR. Matrix metalloproteinase expression and activity in human airway smooth muscle cells. Br J Pharmacol. 2004;142:1318–1324
  30. Xu J, Benyon RC, Leir SH, Zhang S, Holgate ST, Lackie PM. Matrix metalloproteinase-2 from bronchial epithelial cells induces the proliferation of subepithelial fibroblasts. Clin Exp Allergy. 2002;32:881–888
  31. Roeb E, Graeve L, Hoffmann R, Decker K, Edwards DR, Heinrich PC. Regulation of tissue inhibitor of metalloproteinases-1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures. Hepatology. 1993;18:1437–1442
  32. D'Armiento J, Dalal SS, Okada Y, Berg RA, Chada K. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell. 1992;71:955–961
  33. Dunsmore SE, Saarialho-Kere UK, Roby JD, Wilson CL, Matrisian LM, Welgus HG, et al. Matrilysin expression and function in airway epithelium. J Clin Invest. 1998;102:1321–1331
  34. Fligiel SE, Standiford T, Fligiel HM, Tashkin D, Strieter RM, Warner RL, et al. Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury. Hum Pathol. 2006;37:422–430
  35. Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C, Selman M. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest. 2000;117:684–694
  36. Chakrabarti S, Patel KD. Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology. Exp Lung Res. 2005;31:599–621
  37. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood. 2002;100:1160–1167
  38. Huhtala P, Tuuttila A, Chow LT, Lohi J, Keski-Oja J, Tryggvason K. Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells. J Biol Chem. 1991;266:16485–16490
  39. Templeton NS, Stetler-Stevenson WG. Identification of a basal promoter for the human Mr 72000 type IV collagenase gene and enhanced expression in a highly metastatic cell line. Cancer Res. 1991;51:6190–6193

PII: S1569-1993(09)00068-X

doi: 10.1016/j.jcf.2009.06.001

Journal of Cystic Fibrosis
Volume 8, Issue 5 , Pages 338-347 , September 2009

Article Tools

* Image Usage & Resolution